Transfusion Reactions

Hematology/Oncology Clinics of North America

Volumn 30, Issue 3, 2016, Pages 619-634

  Savage, William J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse event; Plasma; Platelet; Reaction; Red blood cell; Transfusion

Indexed keywords

CETIRIZINE; DIPHENHYDRAMINE; DOBUTAMINE; IMMUNOGLOBULIN; INTERLEUKIN 6; PARACETAMOL; RANITIDINE; STEROID; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; AIR EMBOLISM; ALLERGIC REACTION; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; COMPRESSION THERAPY; DISEASE SEVERITY; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBARIC OXYGEN; HYPERVOLEMIA; HYPOTENSION; INCIDENCE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURPURA; REVIEW; SEPSIS; SPLENECTOMY; ADVERSE EFFECTS; BLOOD COMPONENT THERAPY; PROCEDURES;

BLOOD COMPONENT TRANSFUSION; HUMANS;

EID: 84963974379     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2016.01.012     Document Type: Review

References (87)

1. L'Acqua C., Bandyopadhyay S., Francis R.O., et al. Red blood cell transfusion is associated with increased hemolysis and an acute phase response in a subset of critically ill children. Am J Hematol 2015, 90(10):915-920.
2. Janatpour K.A., Kalmin N.D., Jensen H.M., et al. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol 2008, 129:276-281.
3. Josephson C.D., Castillejo M.I., Grima K., et al. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010, 42:83-88.
4. Stowell S.R., Winkler A.M., Maier C.L., et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol 2012, 2012:307093.
5. Donadee C., Raat N.J., Kanias T., et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011, 124:465-476.
6. Hod E.A., Cadwell C.M., Liepkalns J.S., et al. Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions. Blood 2008, 112:891-894.
7. Muylle L., Joos M., Wouters E., et al. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993, 33:195-199.
8. Davenport R.D., Polak T.J., Kunkel S.L. White cell-associated procoagulant activity induced by ABO incompatibility. Transfusion 1994, 34:943-949.
9. Bolton-Maggs P.H. Bullet points from SHOT: key messages and recommendations from the Annual SHOT Report 2013. Transfus Med 2014, 24:197-203.
10. Linden J.V., Wagner K., Voytovich A.E., et al. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000, 40:1207-1213.
11. Kleinman S., Chan P., Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17:120-162.
12. Zimmerman J.L., Shen M.C. Rhabdomyolysis. Chest 2013, 144:1058-1065.
13. Cho Y.S., Lim H., Kim S.H. Comparison of lactated Ringer's solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication. Emerg Med J 2007, 24:276-280.
14. Parekh R., Care D.A., Tainter C.R. Rhabdomyolysis: advances in diagnosis and treatment. Emerg Med Pract 2012, 14:1-15. [quiz: 15].
15. Petz L.D., Calhoun L., Shulman I.A., et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997, 37:382-392.
16. Danaee A., Inusa B., Howard J., et al. Hyperhemolysis in patients with hemoglobinopathies: a single-center experience and review of the literature. Transfus Med Rev 2015, 29(4):220-230.
17. Uhlmann E.J., Shenoy S., Goodnough L.T. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion 2014, 54:384-388.
18. Tormey C.A., Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009, 49:505-512.
19. Brubaker D.B. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions. Transfusion 1990, 30:733-737.
20. Blumberg N., Gettings K.F., Turner C., et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006, 46:1813-1821.
21. Kaufman J., Spinelli S.L., Schultz E., et al. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007, 5:788-796.
22. Shanwell A., Falker C., Gulliksson H. Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin-7, during storage. Vox Sang 2003, 85:206-212.
23. Heddle N.M., Blajchman M.A., Meyer R.M., et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002, 42:556-566.
24. King K.E., Shirey R.S., Thoman S.K., et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004, 44:25-29.
25. Paglino J.C., Pomper G.J., Fisch G.S., et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004, 44:16-24.
26. Sarkodee-Adoo C.B., Kendall J.M., Sridhara R., et al. The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion 1998, 38:229-235.
27. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869.
28. Bowden R.A., Slichter S.J., Sayers M.H., et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991, 78:246-250.
29. National Blood Collection and Utilization Survey Report. 2012. Available at: Accessed August 23, 2015. http://www.hhs.gov/ash/bloodsafety/nbcus/.
30. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
31. Tobian A.A., Savage W.J., Tisch D.J., et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011, 51:1676-1683.
32. Tobian A.A., Fuller A.K., Uglik K., et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014, 54(6):1523-1529.
33. Domen R.E., Hoeltge G.A. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003, 127:316-320.
34. Ponnampalam A., Growe G., Loftus P., et al. Acquired peanut hypersensitivity following platelet transfusion. Transfus Med 2014, 24(6):426-427.
35. Arnold D.M., Blajchman M.A., Ditomasso J., et al. Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med 2007, 167:853-854.
36. Poisson J.L., Riedo F.X., Aubuchon J.P. Acquired peanut hypersensitivity after transfusion. Transfusion 2014, 54:256-257.
37. Branch D.R., Gifford H. Allergic reaction to transfused cephalothin antibody. JAMA 1979, 241:495-496.
38. Savage W.J., Hamilton R.G., Tobian A.A., et al. Defining risk factors and presentations of allergic reactions to platelet transfusion. J Allergy Clin Immunol 2014, 133:1772-1775.e9.
39. Savage W.J., Tobian A.A., Savage J.H., et al. Transfusion and component characteristics are not associated with allergic transfusion reactions to apheresis platelets. Transfusion 2015, 55:296-300.
40. Karafin M., Fuller A.K., Savage W.J., et al. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012, 52(6):1221-1227.
41. O'Leary M.F., Szklarski P., Klein T.M., et al. Hemolysis of red blood cells after cell washing with different automated technologies: clinical implications in a neonatal cardiac surgery population. Transfusion 2011, 51:955-960.
42. Sandler S.G., Eder A.F., Goldman M., et al. The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based. Transfusion 2015, 55(1):199-204.
43. Shimada E., Tadokoro K., Watanabe Y., et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002, 42:766-773.
44. Pagano M.B., Ness P.M., Chajewski O.S., et al. Hypotensive transfusion reactions in the era of prestorage leukoreduction. Transfusion 2015, 55:1668-1674.
45. Cyr M., Hume H.A., Champagne M., et al. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion 1999, 39:1084-1088.
46. Yomtovian R.A., Palavecino E.L., Dysktra A.H., et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006, 46:719-730.
47. Guinet F., Carniel E., Leclercq A. Transfusion-transmitted Yersinia enterocolitica sepsis. Clin Infect Dis 2011, 53:583-591.
48. Kuehnert M.J., Roth V.R., Haley N.R., et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001, 41:1493-1499.
49. Kekre N., Tokessy M., Mallick R., et al. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?. Biol Blood Marrow Transplant 2013, 19:1719-1724.
50. Herwaldt B.L., Linden J.V., Bosserman E., et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011, 155:509-519.
51. Fatalities reported to FDA following blood collection and transfusion. Available at: Accessed September 2, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM459461.pdf.
52. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
53. Zou S., Stramer S.L., Dodd R.Y. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012, 26:119-128.
54. Montgomery S.P., Brown J.A., Kuehnert M., et al. Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006, 46:2038-2046.
55. Biggerstaff B.J., Petersen L.R. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003, 43:1007-1017.
56. Dodd R.Y., Foster G.A., Stramer S.L. Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003 to 2012. Transfus Med Rev 2015, 29:153-161.
57. Levi J.E., Nishiya A., Felix A.C., et al. Real-time symptomatic case of transfusion-transmitted dengue. Transfusion 2015, 55:961-964.
58. Petersen L.R., Epstein J.S. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion 2014, 54:1911-1915.
59. Arellanos-Soto D., B-d l Cruz V., Mendoza-Tavera N., et al. Constant risk of dengue virus infection by blood transfusion in an endemic area in Mexico. Transfus Med 2015, 25:122-124.
60. Chiu C.Y., Bres V., Yu G., et al. Genomic assays for identification of chikungunya virus in blood donors, Puerto Rico, 2014. Emerg Infect Dis 2015, 21:1409-1413.
61. Keil S.D., Bengrine A., Bowen R., et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015, 55:1736-1744.
62. Knutson F., Osselaer J., Pierelli L., et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015, 109(4):343-352.
63. Toy P., Gajic O., Bacchetti P., et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012, 119:1757-1767.
64. Goldman M., Webert K.E., Arnold D.M., et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005, 19:2-31.
65. Vlaar A.P., Juffermans N.P. Transfusion-related acute lung injury: a clinical review. Lancet 2013, 382:984-994.
66. Peters A.L., van Hezel M.E., Juffermans N.P., et al. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev 2015, 29:51-61.
67. Endres R.O., Kleinman S.H., Carrick D.M., et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion 2010, 50:1749-1760.
68. Wiersum-Osselton J.C., Middelburg R.A., Beckers E.A., et al. Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion 2011, 51:1278-1283.
69. Khan S.Y., Kelher M.R., Heal J.M., et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006, 108:2455-2462.
70. Silliman C.C., Fung Y.L., Ball J.B., et al. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009, 23:245-255.
71. Raval J.S., Mazepa M.A., Russell S.L., et al. Passive reporting greatly underestimates the rate of transfusion-associated circulatory overload after platelet transfusion. Vox Sang 2015, 108:387-392.
72. Narick C., Triulzi D.J., Yazer M.H. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012, 52:160-165.
73. Tobian A.A., Sokoll L.J., Tisch D.J., et al. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008, 48:1143-1150.
74. Zhou L., Giacherio D., Cooling L., et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005, 45:1056-1063.
75. Li G., Daniels C.E., Kojicic M., et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion 2009, 49:13-20.
76. Ohto H., Anderson K.C. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996, 10:31-43.
77. Uchida S., Tadokoro K., Takahashi M., et al. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med 2013, 23:416-422.
78. Kopolovic I., Ostro J., Tsubota H., et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015, 126:406-414.
79. Akahoshi M., Takanashi M., Masuda M., et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992, 32:169-172.
80. Hayashi H., Nishiuchi T., Tamura H., et al. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993, 79:1419-1421.
81. Metcalfe P. Platelet antigens and antibody detection. Vox Sang 2004, 87(Suppl 1):82-86.
82. Waters A.H. Post-transfusion purpura. Blood Rev 1989, 3:83-87.
83. Lubenow N., Eichler P., Albrecht D., et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res 2000, 100:115-125.
84. Weisberg L.J., Linker C.A. Prednisone therapy of post-transfusion purpura. Ann Intern Med 1984, 100:76-77.
85. Hamblin T.J., Naorose Abidi S.M., Nee P.A., et al. Successful treatment of post-transfusion purpura with high dose immunoglobulins after lack of response to plasma exchange. Vox Sang 1985, 49:164-167.
86. Mueller-Eckhardt C., Kuenzlen E., Thilo-Korner D., et al. High-dose intravenous immunoglobulin for post-transfusion purpura. N Engl J Med 1983, 308:287.
87. Mirski M.A., Lele A.V., Fitzsimmons L., et al. Diagnosis and treatment of vascular air embolism. Anesthesiology 2007, 106:164-177.